The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director's Dealings

7 Mar 2017 17:27

RNS Number : 7952Y
Premier Veterinary Group PLC
07 March 2017
 

 

 

 

PREMIER VETERINARY GROUP PLC

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

 

 

 

London, UK, 7 March 2017 (LSE: PVG): Premier Veterinary Group plc (the "Company") announces that on 3 March 2017 it granted 40,000 options over its ordinary shares of 10 pence each to Will Evans, Chief Financial Officer and a Director of the Company, under the Company's Enterprise Management Incentive Share Option Plan, with an exercise price of 238.75 pence per share. Following this grant, Will Evans holds 40,000 options.

 

The options will become exercisable on the third anniversary of the date of grant and remain exercisable up to and including the tenth anniversary of the date of grant, to the extent that the performance targets applicable to the options have been met. As disclosed in the Company's annual report and accounts for the year ended 30 September 2016, the performance targets are based on the growth in the number of pets on the Company's preventative healthcare programme for pets (Premier Pet Care Plan) to a pre-determined level, and the Company's share price increasing to at least twice the share price at the date of grant.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name

WILLIAM EDWARD FRANK EVANS

2

Reason for the notification

 

a)

Position/status

 

Chief Financial Officer/Executive Director

b)

Initial notification/ Amendment

 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

Premier Veterinary Group plc

 

b)

LEI

 2138009B5L8VQUZ9A719

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of £0.10 each

 

 

 

ISIN: GB00BSZLMS59

b)

Nature of the transaction

Grant of options to acquire shares

 

c)

Price(s) and volume(s)

40,000 options to acquire ordinary shares at an exercise price of 238.75 pence per share 

d)

Aggregated information

 

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

3 March 2017

 

f)

Place of the transaction

Outside a trading venue

 

 

For further information, please contact:

 

Premier Veterinary Group plc Tel:  +44(0)117 970 4127

 

Dominic Tonner, Chief Executive Officer

Will Evans, Chief Financial Officer

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHZMGGFNNVGNZM
Date   Source Headline
1st Mar 201310:50 amRNSForm 8.3 - [Ark Therapeutics]
26th Feb 20135:35 pmRNSHolding(s) in Company
26th Feb 20139:33 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:55 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:27 amRNSHolding(s) in Company
22nd Feb 20132:41 pmRNSHolding(s) in Company
21st Feb 20131:24 pmPRNForm 8.3 - Ark Therapeutics plc
21st Feb 201310:56 amRNSHolding(s) in Company
20th Feb 201312:54 pmPRNForm 8.3 - Ark Therapeutics plc
20th Feb 201312:11 pmRNSForm 8.3 - [Ark Therapeutics Group PLC]
19th Feb 20134:40 pmRNSSecond Price Monitoring Extn
19th Feb 20134:35 pmRNSPrice Monitoring Extension
15th Feb 201312:57 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Feb 201310:39 amPRNForm 8.3 - Ark Therapeutics Group plc
12th Feb 201312:25 pmRNSHolding(s) in Company
7th Feb 20133:05 pmRNSHolding(s) in Company
7th Feb 20131:41 pmPRNForm 8.3 - Ark Therapeutics Group
6th Feb 20134:43 pmRNSForm 8.3 - Ark Therapeutics
6th Feb 201311:18 amPRNForm 8.3 - Ark Therapeutics Group
6th Feb 201311:02 amRNSForm 8 (OPD)
5th Feb 20134:35 pmRNSPrice Monitoring Extension
5th Feb 20132:48 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Feb 20132:43 pmRNSForm 8.3 - Ark Therapeutics Group Plc
4th Feb 20131:10 pmRNSForm 8.3 - Ark Therapeutics
4th Feb 201310:11 amRNSForm 8.3 - [Ark Therapeutics]
1st Feb 20133:10 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Feb 20132:53 pmRNSForm 8.3 - Ark Therapeutics Amendment
1st Feb 201312:41 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 20133:42 pmRNSForm 8.3 - Ark Therapeutics Group PLC
31st Jan 20131:40 pmRNSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 20131:31 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 201312:02 pmRNSForm 8.3 - ARK Therapeutics plc
31st Jan 201311:51 amBUSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 201311:14 amPRNForm 8.3 - Ark Therapeutics Group
30th Jan 20134:03 pmRNSForm 8.3 - Ark Therapeutics Group Plc
30th Jan 20137:00 amRNSStrategic Review Update
24th Jan 20133:33 pmRNSHolding(s) in Company
21st Jan 20137:00 amRNSCompany Update
4th Dec 20123:40 pmRNSBlocklisting Six Monthly Return
30th Nov 20127:00 amRNSFrench Tax Credit for Research and Development
8th Nov 20127:00 amRNSInterim Management Statement
15th Oct 20127:00 amRNSRe Agreement
26th Sep 20127:00 amRNSManufacturing Agreement Update
29th Aug 20127:00 amRNSHalf Yearly Report
24th Aug 20124:40 pmRNSSecond Price Monitoring Extn
24th Aug 20124:35 pmRNSPrice Monitoring Extension
14th Aug 20127:00 amRNSRe Agreement
25th Jul 20127:00 amRNSManufacturing Partnership
5th Jul 20127:00 amRNSDirectorate Change
11th Jun 20127:00 amRNSAppointment of New Head of Business Development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.